Showing 1 - 10 of 27 Breast Cancers

Status: Enrolling

Investigator: Jenny Chang

Study Coordinator:

Phone:

The purpose of this research study is to test the safety and effectiveness of docetaxel chemotherapy and pembrolizumab plus adenoviral-mediated interleukin-12 (ADV/IL-12) gene therapy in patients with anthracycline-refractory, triple negative br ... Read more >

Status: Enrolling

Investigator: Warren Ellsworth

Study Coordinator:

Phone:

This is a multicenter registry study to collect utilization, safety, and outcomes data from medical record chart review of nerve reconstruction procedures throughout the body with Avance® Nerve Graft. Addendum 1 (MATCH) establishes a comparat ... Read more >

Status: Enrolling

Investigator: Jenny Chang

Study Coordinator:

Phone:

Breast implants are the most common way of rebuilding the shape of the breasts after breast cancer surgery. However, current breast implants cannot completely match individual differences in breast shape. It is also often difficult to match the ... Read more >

Status: Enrolling

Investigator: Aldona Spiegel

Study Coordinator:

Phone:

This is a multicenter registry study to collect utilization, safety, and outcomes data from medical record chart review of nerve reconstruction procedures throughout the body with Avance® Nerve Graft. Addendum 1 (MATCH) establishes a comparat ... Read more >

Status: Open Not Enrolling

Investigator: Jenny Chang

Study Coordinator:

Phone:

This is a pilot study is evaluating the effect of hydroxytyrosol, a component of Olive oil, on mammographic density in women at high risk of breast through assessing whether mammographic density is reduced in women at high risk of breast cancer ... Read more >

Status: Open Not Enrolling

Investigator: Sandra Templeton

Study Coordinator: Juan Morales Viera

Phone: 786.803.2333

This is a prospective cohort study for patients diagnosed with ductal carcinoma in situ (DCIS) of the breast. The primary objective of the study is to create a de-identified database of patients, test results, treatment decisions and outcomes th ... Read more >

Status: Open Not Enrolling

Investigator: Polly Niravath

Study Coordinator: Juan Morales Viera

Phone: 786.803.2333

This randomized phase III trial studies standard or comprehensive radiation therapy in treating patients with early-stage breast cancer who have undergone surgery. Radiation therapy uses high-energy x rays to kill tumor cells. It is not yet know ... Read more >

Status: Open Not Enrolling

Investigator: Polly Niravath

Study Coordinator:

Phone:

The main purpose of this study is to learn if the usual chemotherapy given before surgery (neoadjuvant therapy) for breast cancer plus the experimental drug, atezolizumab, is better than the usual chemotherapy plus a placebo. (A placebo is a dru ... Read more >

Status: Open Not Enrolling

Investigator: Dharamvir Jain

Study Coordinator: Toniva Boone

Phone: 713.441.0686

This randomized phase III trial studies how well paclitaxel, trastuzumab, and pertuzumab with or without atezolizumab works in treating patients with breast cancer that has spread to other parts of the body (metastatic). Drugs used in chemothera ... Read more >

Status: Open Not Enrolling

Investigator: Polly Niravath

Study Coordinator: Mary Rose Silvas

Phone: 713.441.1952

This randomized phase III trial studies how well pembrolizumab works in treating triple-negative breast cancer. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. ... Read more >

Status: Enrolling

Investigator: Polly Niravath

Study Coordinator:

Phone:

A single arm pilot study of 20 patients will be used to determine the feasibility of EA as a treatment for cancer survivors who have been treated with curative intent, but who have persistent CIPN for ?3 months after the cancer treatment is comp ... Read more >

Status: Open Not Enrolling

Investigator: Polly Niravath

Study Coordinator: Mary Rose Silvas

Phone: 713.441.1952

This phase II trial studies how well biopsy of breast after chemotherapy works in predicting pathologic response in patients with stage II-IIIA breast cancer undergoing breast conserving surgery. Tumor tissue collected from biopsy before surgery ... Read more >

Status: Open Not Enrolling

Investigator: Polly Niravath

Study Coordinator: Toniva Boone

Phone: 713.441.0686

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of breast cancer cells, either by killing the cells or by stopping them from dividing. Giving the drugs in different combinations may kill more breast cancer cells. ... Read more >

Status: Open Not Enrolling

Investigator: Polly Niravath

Study Coordinator: Raquel Araujo

Phone: 713.363.9363

This is a Phase Ib/II study assessing the maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), recommended Phase 2 dose (RP2D), and efficacy of L-NMMA when combined with docetaxel in refractory locally advanced or metastatic triple neg ... Read more >

Status: Open Not Enrolling

Investigator: Jenny Chang

Study Coordinator:

Phone:

Hormone receptor positive breast cancer HRBC is the most common cause of BC-related death. HRBC is characterized by a non-immunogenic microenvironment and consequently, modest responses have been observed with immune checkpoint blockade ICB alon ... Read more >

Status: Open Not Enrolling

Investigator: Polly Niravath

Study Coordinator: Tanya Khan

Phone: 346.238.5655

The reason for this trial is to compare DS-8201a to other treatments being used for HER2-low breast cancer that has spread to other parts of the body. DS-8201a is a new medicine for breast cancer that has not been approved yet by the Food and ... Read more >

Status: Open Not Enrolling

Investigator: Polly Niravath

Study Coordinator:

Phone:

This study is designed to compare the anti-tumor activity as well as the safety and efficacy of DS-8201a versus T-DM1 in HER2-positive, unresectable and/or metastatic breast cancer subjects previously treated with trastuzumab and taxane. ... Read more >

Status: Open Not Enrolling

Investigator: Polly Niravath

Study Coordinator:

Phone:

Primary Objective: • To compare the efficacy of DS-8201a to investigator’s choice by means of progression-free survival (PFS). Secondary Objectives: • To further investigate the efficacy of DS-8201a compared to investigator’s choice on: ? ... Read more >

Status: Enrolling

Investigator: Jenny Chang

Study Coordinator: Ezinne Onuoha

Phone: 832.874.9052

The study will investigate if a one month drug holiday from the CDK4/6 inhibitor drug, abemaciclib, will restore the body's sensitivity to the drug and make the subsequent treatment of abemaciclib plus fulvestrant more effective. ... Read more >

Status: Enrolling

Investigator: Jenny Chang

Study Coordinator: Juan Morales Viera

Phone: 786.803.2333

This is a Phase I/Ib study testing the safety and preliminary efficacy of olaparib and vorinostat when used together in participants with relapsed/refractory and or metastatic breast cancer. Cancer cells grow in an uncontrolled manner and this c ... Read more >

Status: Enrolling

Investigator: Jenny Chang

Study Coordinator: Juan Morales Viera

Phone: 786.803.2333

The purpose of this research study is to test the safety and effectiveness of using durvalumab with trastuzumab and pertuzumab in participants with human epidermal growth factor receptor 2 (HER2)-enriched breast cancer. ... Read more >

Status: Open Not Enrolling

Investigator: Dharamvir Jain

Study Coordinator:

Phone:

This is a prospective, two arm, international, multicenter, randomized, open-label Phase III study evaluating the addition of 2 years of palbociclib to standard adjuvant endocrine therapy for patients with HR+ / HER2- early breast cancer (EBC). ... Read more >

Status: Open Not Enrolling

Investigator: Polly Niravath

Study Coordinator:

Phone:

This is an open-label, randomized, multicenter Phase 3 study to compare the efficacy and safety of Sacituzumab Govitecan versus TPC in subjects with metastatic or locally recurrent inoperable HR+/HER2- MBC, after failure of at least 2, and no mo ... Read more >

Status: Open Not Enrolling

Investigator: Jenny Chang

Study Coordinator:

Phone:

The major purpose of this research study is to better understand how therapy works on different patients. This study is being offered to patients with a diagnosis of advanced or metastatic breast cancer who have failed anthracycline based therap ... Read more >

Status: Open Not Enrolling

Investigator: Jenny Chang

Study Coordinator: Steven Hepp

Phone: 802.793.3352

This is a Phase II trial to determine the efficacy and safety of stereotactic body radiation therapy (SBRT) and in situ oncolytic virus therapy used as a window of opportunity treatment before pembrolizumab in patients with metastatic triple neg ... Read more >

Status: Enrolling

Investigator: Polly Niravath

Study Coordinator: Mary Rose Silvas

Phone: 713.441.1952

This study is investigating whether breast cancer patients who experience vaginal dryness while on anti-estrogen treatment could benefit from either vaginal estrogen or from a vaginal moisturizer called Replens. ... Read more >

Status: Open Not Enrolling

Investigator: Polly Niravath

Study Coordinator:

Phone:

RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy, using tamoxifen citrate, may fight breast cancer by blocking the use of estrogen by the tumor cells. Aromatase inhibitors, such as anastrozole, letrozole, and exem ... Read more >